Although the mutation frequency was low, Norquist et al. demonstrated that PALB2 mutation carriers had a significantly higher risk of ovarian cancer compared with the NHLBI Exome Sequencing Project (OR, 10.2; 95% CI, 2.2–47.0; p < 0.001) or the Exome Aggregation Consortium database (OR, 4.4; 95% CI, 2.1–9.1; p < 0.001) (8). Here, PALB2 is linked to ovarian carcinoma.